ArticleJournal of medical case reports2026
Newly diagnosed high-risk localized prostate cancer after multiple [177Lu]Lu-PSMA radioligand therapy in the context of metastatic parotid carcinoma: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate-specific membrane antigen-direct radioligand therapy (PSMA RLT) is primarily used to treat castration-resistant metastatic prostate cancer (PCa) after prior treatment options have been exhausted. Occasionally, other tumor entities, such as parotid carcinoma in this case, also express prostate-specific membrane antigen (PSMA) on their cell surface. CASE DESCRIPTION: We present the case of a white 67-year-old patient newly diagnosed with locally advanced PCa despite multiple cycles of Lutetium-177-labeled prostate-specific membrane antigen radioligand therapy ([177Lu]Lu-PSMA-RLT), which he had received for metastatic parotid carcinoma. Interestingly, no regressive histopathological changes were found in the prostate biopsy specimen, despite given PSMA-expression in the prostate.
conclusionThe potential selection of high-grade disease, which appears to have occurred in this patient, underscores the need for further large-scale histopathological examination and thorough follow-up of the current investigational approaches using [177Lu]Lu-PSMA-RLT in high-risk prostate cancer (PCa).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.